Dr C Pellat-Deceunynck obtained her PhD degree in 1992 for her work on nitric oxide activity against cancer cells at Curie Institute, Paris. During her post-doc in Nantes, she identified specific markers for human plasma cells, characterized the human plasma cell series during the B to PC differentiation by identifying plasmablasts in vivo and in vitro, and demonstrated the heterogeneity of human myeloma cells through the expression of cluster of differentiation and tumor antigens. She joined CNRS in 2000. She developed and characterized a unique myeloma cell line collection in order to decipher the molecular and functional tumor heterogeneity related to the oncogenomic diversity, leading to her founding of Myelomax SAS in 2010. Since 2010, she extended her expertise to mantle cell lymphoma and focused her basic studies on the identification and targeting of vulnerabilities related to p53 deficiencies and dysregulations of the BCL2 network in B-cell malignancies. She is team leader and deputy director of Nantes Angers Research Cancer in Immunology and Oncology (CRCI2NA), deputy director of the SIRIC ILIAD program. She is member of the Scientific Committee of Ligue Nationale Control le Cancer.